key: cord-0965253-kxdfnykd
authors: Grant, Rogan A.; Morales-Nebreda, Luisa; Markov, Nikolay S.; Swaminathan, Suchitra; Querrey, Melissa; Guzman, Estefany R.; Abbott, Darryl A.; Donnelly, Helen K.; Donayre, Alvaro; Goldberg, Isaac A.; Klug, Zasu M.; Borkowski, Nicole; Lu, Ziyan; Kihshen, Hermon; Politanska, Yuliya; Sichizya, Lango; Kang, Mengjia; Shilatifard, Ali; Qi, Chao; Lomasney, Jon W.; Argento, A. Christine; Kruser, Jacqueline M.; Malsin, Elizabeth S.; Pickens, Chiagozie O.; Smith, Sean B.; Walter, James M.; Pawlowski, Anna E.; Schneider, Daniel; Nannapaneni, Prasanth; Abdala-Valencia, Hiam; Bharat, Ankit; Gottardi, Cara J.; Budinger, GR Scott; Misharin, Alexander V.; Singer, Benjamin D.; Wunderink, Richard G.
title: Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia
date: 2021-01-11
journal: Nature
DOI: 10.1038/s41586-020-03148-w
sha: 76d6eeb67a9e85d9ca317f9b564dc783bdb3e95e
doc_id: 965253
cord_uid: kxdfnykd

Some patients infected with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) develop severe pneumonia and the acute respiratory distress syndrome (ARDS)(1). Distinct clinical features in these patients have led to speculation that the immune response to virus in the SARS-CoV-2-infected alveolus differs from other types of pneumonia(2). We collected bronchoalveolar lavage fluid samples from 88 patients with SARS-CoV-2-induced respiratory failure and 211 patients with known or suspected pneumonia from other pathogens and subjected them to flow cytometry and bulk transcriptomic profiling. We performed single-cell RNA-seq on 10 bronchoalveolar lavage fluid samples collected from patients with severe COVID-19 within 48 hours of intubation. In the majority of patients with SARS-CoV-2 infection, the alveolar space was persistently enriched in T cells and monocytes. Bulk and single-cell transcriptomic profiling suggested that SARS-CoV-2 infects alveolar macrophages, which in turn respond by producing T cell chemoattractants. These T cells produce interferon-gamma to induce inflammatory cytokine release from alveolar macrophages and further promote T cell activation. Collectively, our results suggest that SARS-CoV-2 causes a slowly-unfolding, spatially limited alveolitis in which alveolar macrophages harboring SARS-CoV-2 and T cells form a positive feedback loop that drives persistent alveolar inflammation.

patients account for almost all of the morbidity and mortality associated with the infection 1, [3] [4] [5] . The reported 20-40% mortality among patients with severe SARS-CoV-2 pneumonia, combined with a severe systemic inflammatory response in some patients, have led to speculation that the pathobiology of SARS-CoV-2 pneumonia is distinct from pneumonia caused by other respiratory viral and bacterial pathogens 2 .

We obtained bronchoalveolar lavage (BAL) samples from 88 patients with respiratory failure secondary to severe SARS-CoV-2 pneumonia and compared them with BAL samples prospectively collected before and during the pandemic from 211 patients with pneumonia secondary to other pathogens and 42 intubated patients without pneumonia. For many patients, we were able to obtain samples within 48 hours of intubation and sequentially over the course of the illness, allowing us to gain insights about the early pathogenesis and progression of COVID-19-induced respiratory failure. We profiled BAL samples using flow cytometry and performed bulk transcriptomic profiling of alveolar macrophages. Additionally, we performed single-cell RNA-sequencing on BAL fluid collected less than 48 hours after intubation from 10 patients with severe SARS-CoV-2 pneumonia. We used these data to develop a testable hypothesis to explain SARS-CoV-2 pathobiology (Fig. 1a) .

Samples were collected as part of the Successful Clinical Response in Pneumonia Therapy (SCRIPT) Systems Biology Center, an observational study of patients with severe pneumonia, defined as those requiring mechanical ventilation. We prospectively enrolled 88 of the 179 patients with SARS-CoV-2-induced pneumonia and respiratory failure requiring mechanical ventilation in our intensive care unit (ICU) (Fig. 1b, Extended Data Fig. 1a -c; Extended Data Table 1) .

We compared patients with COVID-19 with 253 mechanically ventilated patients enrolled in the two years before and during the pandemic. These included patients intubated for reasons other than pneumonia (non-pneumonia control), patients diagnosed with severe non-SARS-CoV-2 viral pneumonia (other viral pneumonia), or patients with severe pneumonia secondary to bacterial or fungal pathogens (other pneumonia). Compared with these patients, patients with SARS-CoV-2 pneumonia were similar in age, race, and sex, but had a significantly higher self-reported Hispanic or Latino ethnicity and body mass index ( Fig. 1c f, Extended Data Table 1 ).

Severity of illness estimated using the sequential organ failure assessment (SOFA) score and the acute physiology score (APS) was similar in patients with SARS-CoV-2 pneumonia compared with other pneumonia and was comparable to that observed in a recent study of ARDS 6 (Fig. 1g ,h, Extended Data Table 1 ). Patients with severe SARS-CoV-2 pneumonia had longer lengths of stay in the ICU and required longer periods of ventilation compared with all pneumonia and non-pneumonia controls (Fig. 1i,j) . On the day of their first BAL, patients with severe SARS-CoV-2 pneumonia had increased levels of C-reactive protein compared with patients with other pneumonias, while other biomarkers of inflammation were similar (Extended Data Fig. 1d-i) . The BAL sampling rate per day among patients with COVID-19 was not higher than the sampling rate among patients with other pneumonias (see Extended Data Fig. 1j-l) . Mortality was not different between patients with SARS-CoV-2 pneumonia compared with the entire cohort (Fig. 1k ).

We began by performing flow cytometry on BAL samples collected within 48 hours of intubation ( Fig. 2a,b, Extended Data Fig. 2a-e) . We found that, despite severe pneumonia requiring mechanical ventilation, only 31% of patients with severe COVID-19 exhibited neutrophilia in BAL fluid (Fig. 2a,b) . Instead, we found that in patients with severe SARS-CoV-2 pneumonia, the alveolar space was significantly enriched for CD4+ and CD8+ T cells and monocytes (Fig. 2a,b, Extended Data Fig. 3a ).

As macrophages respond to alterations in their micro-environment 7 , we reasoned that changes in the alveolar macrophage transcriptome may reflect unique features of the SARS-CoV-2-infected alveolus. We isolated alveolar macrophages from BAL fluid collected within the first 48 hours after intubation from patients with severe SARS-CoV-2 pneumonia and compared them with alveolar macrophages from patients with pneumonia secondary to other pathogens, non-pneumonia controls, and healthy volunteers. k-means clustering of the 1,194 significantly variable genes (q < 0.05, likelihood-ratio test) across diagnosis identified 5 clusters (Fig. 2c , Supplemental Data Files 1-3). Notably, the majority of patients with COVID-19 clustered together. Cluster 1 contained genes specifically upregulated in patients with COVID-19 and was characterized by genes involved in the response to interferon (IFN). Cluster 1 also included genes encoding the chemokines CCL7, CCL8, and CCL13, which drive recruitment of monocytes and T cells.

To detect viruses in alveolar macrophages we aligned RNA-seq reads to a hybrid genome including the human, SARS-CoV-2, and Influenza A/California/07/2009 reference genomes. An additional negative-strand SARS-CoV-2 transcript, which is transiently formed during its replication, was added to the SARS-CoV-2 genome to detect replicating virus 8 . We detected SARS-CoV-2 transcripts in alveolar macrophage transcriptomes from 67% of samples with PCR-confirmed SARS-CoV-2 infection. In 38% of these samples, we detected both positiveand negative-strand SARS-CoV-2 transcripts (Extended Data Fig. 3b ,c).

Unlike other types of pneumonia, SARS-CoV-2 pneumonia is characterized by a long duration between symptom onset and the development of respiratory failure (6-12 days) and a prolonged course of mechanical ventilation (Fig. 1b,i,j) 1, 4 . To determine whether the unique cellular composition of the BAL fluid and the interferon response signature in alveolar macrophages persists over the course of the disease, we analyzed samples obtained early after intubation (<48 hours) and all samples obtained >48 hours after intubation. Hierarchical clustering of BAL samples from all time points from serially sampled patients as well as direct pairwise comparison of early (<48 hours after intubation) versus late (>48 hours after intubation) samples between groups demonstrated that, in comparison with BAL samples from other pneumonia, samples from patients with COVID-19 were persistently enriched for T cells (Fig. 3a,b ; Extended Data Fig. 4a,b) . These findings persisted in the 40% of patients with severe SARS-CoV-2 pneumonia who had a superinfecting pathogen detected over the course of mechanical ventilation (Extended Data Table 2 ). Nevertheless, BAL fluid neutrophils were increased in samples collected after 48 hours of mechanical ventilation in patients with COVID-19, likely attributable to the duration of mechanical ventilation and the attendant risk of bacterial superinfection (Extended Data Fig. 4c) .

We then performed RNA-seq on alveolar macrophages isolated early (<48 hours) and later over the course of mechanical ventilation. k-means clustering of the 2,323 significantly variable genes (q < 0.05, likelihood-ratio test) across diagnoses identified five clusters ( Fig.  3c ; Extended Data Fig. 5a ; Supplemental Data Files 1-3). Of note, genes and related GO biological processes associated with these clusters were remarkably similar to those identified in samples collected within 48 hours after intubation (Fig. 2c) . Specifically, samples from patients with COVID-19 continued to cluster together and were differentiated by increased expression of genes in Cluster 1, which was enriched for interferon-response genes and T cell chemokines (Fig. 3c , Extended Data Fig. 5a ,b).

In order to identify gene modules in alveolar macrophages that distinguish pneumonia type and outcome, we performed weighted gene co-expression network analysis (WGCNA) (Extended Data Fig. 5c , Supplemental Data File 1). Module 15 was enriched for interferonresponsive genes and correlated with the detection of SARS-CoV-2 transcripts, levels of Creactive protein, CD8+ T cell abundance, and COVID-19 diagnosis (R = 0.28, 0.30, 0.28, 0.25, respectively). Notably, all SARS-CoV-2 genes included in this analysis were assigned to this module, further underscoring the relevance of the disease diagnosis category. Consistent with the results of k-means clustering, module 15 was enriched for type I and type II interferon response genes (GO:0060337, GO:0060333). We observed a significant negative correlation between interferon signaling and the duration of mechanical ventilation (Extended Data Fig. 5d-f ). In addition, we identified modules related to macrophage maturation, including Module 4, which exhibited a positive correlation with the percentage of CD206 hi alveolar macrophages (R = 0.61), and Module 12, which exhibited a negative correlation with percentage of CD206 hi macrophages (R = −0.62) (Extended Data Fig. 5c ). The unique features of SARS-CoV-2 pneumonia are further illustrated by a UMAP projection of all bulk RNA-seq samples, which separated largely by diagnosis, module 15 gene expression, and abundance of T cells (Extended Data Fig. 5g ).

We took advantage of the serial samples collected from the same patients with COVID-19 and explored the relationship between expression of canonical interferon-response genes and patient outcomes. Analysis of the serial samples from patients with COVID-19 who were discharged home (5 patients) or to an inpatient facility (2 patients) demonstrated decreased expression of interferon-response genes as the disease progressed, while in patients who were discharged to a long-term acute care facility (LTAC, 5 patients) or died (2 patients) the expression of interferon-response genes was largely unchanged (Extended Data Fig. 5h ). Consistent with these findings, we observed a significant negative correlation between abundance of SARS-CoV-2 transcripts in patients with confirmed COVID-19 and the time since intubation (ρ = −0.49, Spearman correlation; Extended Data Fig. 5i ).

We performed single-cell RNA-seq on 10 patients with COVID-19 from whom BAL samples were collected within 48 hours of intubation (Fig. 4a , Extended Data Fig. 6a-d) . We included two additional patients, one with bacterial pneumonia and one non-pneumonia control (Extended Data Fig. 6e-h) . Analysis of an integrated object resolved multiple clusters corresponding to macrophages and other cell types (Supplemental Data File 4). Alveolar macrophages contained six clusters. Four clusters of monocyte-derived alveolar macrophages (MoAM) were characterized by CCL2 expression and gradually increasing expression of genes associated with alveolar macrophage maturation. The other two clusters expressed markers of tissue-resident alveolar macrophages (TRAM) (Fig. 4b , Extended Data Fig. 6a ). We did not detect expression of type I interferons in our single-cell dataset or in other publicly available single-cell RNA-seq datasets 9,10 obtained from BAL fluid later in the clinical course of patients with COVID-19 (data not shown). In contrast, expression of type II interferon (IFNG) was detected in T cells from all 10 patients with COVID-19 ( Fig.  4c , Extended Data Fig. 6b ). These results suggest that the interferon-response gene signature we observed in alveolar macrophages may be in response to IFNγ released from activated T cells.

As expected, positive-and negative-strand SARS-CoV-2 transcripts were detected in epithelial cells. Surprisingly, we also detected SARS-CoV-2 transcripts in migratory CCR7+ dendritic cells, MoAM2 and TRAM2, which do not express ACE2 (Fig. 4d , Extended Data Fig. 6c ). Coronaviruses generate large numbers of positive-strand transcripts from a single negative-strand template 8, 11 . Consistent with this known biology, we detected more transcripts for positive compared with negative strands in both our single-cell and bulk RNA-seq data (Extended Data Fig. 3c , Extended Data Fig. 6d and Fig. 4d ). These results suggest that alveolar macrophages harbor SARS-CoV-2 and that they may support viral replication as has been reported for SARS-CoV and MERS-CoV 12-14 .

TRAM2 harboring SARS-CoV-2 exhibited a distinct transcriptional program compared with uninfected TRAM1 (Fig. 4b ,h, Extended Data Fig. 6g ,h, Supplemental Data File 5). In patients with COVID-19, genes distinguishing infected TRAM2 from non-infected TRAM1 included several chemokines and cytokines important for T cell and monocyte recruitment, such as CCL4, CCL20, CXCL10 and CXCL11. TRAM2 also expressed genes IL1B, TNFSF10, and DEFB1 (Fig. 4b ,e-h, Supplemental Data File 6). Finally, infected TRAM2 were marked by increased expression of interferon-response genes compared with noninfected TRAM1 (Fig. 4b,h ). IL-6 induces the transcription of clotting factors in the liver and tissue factor in the endothelium to promote thrombosis, and elevated levels of IL-6 predict mortality in patients with COVID-19 [15] [16] [17] . Because single-cell RNA-seq analyses of peripheral blood from patients with COVID-19 failed to identify circulating cells producing IL-6 18, 19 , some have suggested that IL-6 is produced by inflammatory cells in the alveolus 17 . In our dataset, the overall expression of IL6 was low and was primarily restricted to very immature MoAM1 originating from two patients (Extended Data Fig. 7a) . Furthermore, the expression of IL6 in BAL fluid cells from patients with COVID-19 was comparable to previously reported IL6 expression in alveolar macrophages from patients with later-stage COVID-19 9 and lower than IL6 expression observed in stromal and endothelial cells from a published single-cell RNA-seq dataset describing the healthy or fibrotic lung 20 . Consistently, in our bulk RNAseq data from flow cytometry-sorted alveolar macrophages, IL6 expression was not different between patients with pneumonia secondary to SARS-CoV-2 compared with other respiratory pathogens, although it was higher than in healthy controls, in whom IL6 transcripts were never detected (Extended Data Fig. 5b ). While we did not sample neutrophils, Liao et al. and Chua et al. did not detect increased neutrophil IL6 expression in their single-cell RNA-seq datasets of BAL fluid from patients with SARS-CoV-2 pneumonia 9,10 .

In murine models of influenza A viral pneumonia, IFNγ drives apoptosis of tissue-resident alveolar macrophages 21 . We therefore wondered whether the CD206 hi alveolar macrophages in patients with severe SARS-CoV-2 pneumonia were truly tissue-resident alveolar macrophages or maturing monocyte-derived alveolar macrophages. We performed cell-type deconvolution of our bulk RNA-seq data and found that in patients with SARS-CoV-2 pneumonia only a small fraction of alveolar macrophages were tissue-resident alveolar macrophages. Instead, the majority of alveolar macrophages were monocyte-derived alveolar macrophages (MoAM3) (Extended Data Fig. 7b ,c).

The BAL procedure samples cells from a lung segment, which includes many thousands of alveoli. Therefore, the detection of infected and non-infected alveolar macrophages in the same BAL fluid sample in our single cell RNA-seq data suggests infected and uninfected alveoli will co-exist within a single lung segment. To test this prediction, we examined lung tissue from a patient who died from SARS-CoV-2 pneumonia while forgoing treatments, save comfort measures. Using smFISH we detected positive-and negative-strand SARS-CoV-2 transcripts in the lung epithelium and alveolar macrophages ( Fig. 4i and Supplemental Data File 7, Supplemental Data Video 1). Positive-strand SARS-CoV-2 transcripts exhibited diffuse cytoplasmic staining, and the number of punctae exceeded that of negative transcripts. As predicted from our model of lung infection, cells containing SARS-CoV-2 transcripts were also detected in a spatially-restricted manner, as regions of the lung containing the virus were adjacent to the regions with nearly-normal architecture where viral particles were absent.

A minority of patients with severe SARS-CoV-2 pneumonia develop respiratory failure, but it is these patients who account for almost all of the morbidity, mortality, and socioeconomic cost associated with the COVID-19 pandemic. We systematically sampled the alveolar space in patients with new-onset respiratory failure secondary to SARS-CoV-2 pneumonia and compared these samples with those from a large comparison cohort of patients with pneumonia from other respiratory pathogens collected before and during the pandemic. We used these data to develop a model for the unique pathobiology of SARS-CoV-2 pneumonia (Fig. 1a) . Our model proposes that SARS-CoV-2 initially infects and replicates in epithelial cells in the nasopharynx, which express relatively high levels of ACE2 in comparison with epithelial cells in lower airways or the distal lung 22, 23 . Whether by progressive movement distally in the tracheobronchial tree or via aspiration of nasopharyngeal contents, some virus gains access to the distal alveolar space. In the alveolar space, SARS-CoV-2 infects alveolar epithelial cells and tissue-resident alveolar macrophages 24 . A transcriptional program is activated within infected tissue-resident alveolar macrophages that promotes the recruitment of memory T cells to the alveolar space. There, memory T cells become activated, releasing IFNγ, which activates tissue-resident alveolar macrophages harboring SARS-CoV-2. Eventually, these tissue-resident alveolar macrophages die and monocyte-derived alveolar macrophages are recruited, which in turn become infected with SARS-CoV-2 to sustain the inflammatory signaling loop with T cells. These infected alveolar macrophages may act as a Trojan horse, transferring the virus to adjacent lung regions, slowly propagating SARS-CoV-2 infection across the lung.

Our model is informed by a wealth of causal data generated in cell and animal models of SARS-CoV-2 and the related coronaviruses SARS-CoV and MERS-CoV. SARS-CoV-2 proteins have been shown to suppress type I interferon responses [24] [25] [26] , and we did not detect ongoing expression of type I interferons in our bulk or single-cell RNA-seq data 25, 27 . Our data suggesting that SARS-CoV-2 replicates in alveolar macrophages are consistent with reports that SARS-CoV, MERS-CoV, and SARS-CoV-2 can infect macrophages in vitro [12] [13] [14] 24, 28 , and the detection of SARS-CoV-2 in alveolar macrophages in autopsy studies of patients with SARS-CoV-2 pneumonia 29 .

Alveolar macrophage infection might result from phagocytosis of infected alveolar epithelial cells followed by viral escape from the lysosome. Alternatively, alveolar macrophages might be directly infected, as was shown for SARS-CoV and MERS-CoV 12, 14 . Finally, antibodydependent enhancement has been suggested from cell and animal models of SARS-CoV and MERS-CoV infection 30, 31 .

Activation of memory T cells leads to IFNγ production, local proliferation of activated memory T cells, mounting of inflammatory responses, and recruitment of monocytes and T cells. We observed enrichment of CD4+ and CD8+ T cells in the alveolar space of patients with SARS-CoV-2 pneumonia relative to pneumonia secondary to other pathogens. Furthermore, our single-cell RNA-seq data confirmed production of IFNγ by both CD4+ and CD8+ T cells. These results raise the question of how T cells in the alveolar space become activated following SARS-CoV-2 infection. While tissue-resident alveolar macrophages are poor antigen-presenting cells and do not convert naïve T cells into effector T cells 32 , a low level of antigen presentation by alveolar macrophages might be sufficient to activate pre-existing memory T cells that cross-react with SARS-CoV-2. Existence of such cross-reactive memory T cells has been reported for SARS-CoV 33 and for SARS-CoV-2 [34] [35] [36] [37] [38] . A larger number of SARS-CoV-2 cross-reactive memory T cells was observed independently in elderly people and in patients with severe COVID-19, compared with those with mild COVID-19 38 . These cross-reactive T cells exhibited lower avidity and reduced antiviral responses in response to stimulation with SARS-CoV-2 peptides compared with T cells from patients who recovered from COVID-19. This mechanism might explain the epidemiology of severe SARS-CoV-2 pneumonia, which disproportionately affects elderly individuals.

Single-cell RNA-seq atlases and smFISH studies of the normal human lung show that only a small number of alveolar epithelial cells express ACE2, the gene encoding the receptor for SARS-CoV-2 entry 22, 23 . In contrast, the sialic acid residues that serve as receptors for influenza A virus are abundantly expressed in alveolar type 2 cells 22 . Thus, while influenza A infects large numbers of cells leading to rapid viral replication, widespread injury, robust antiviral responses, and death of infected epithelial cells, infection by SARS-CoV-2 is likely to lead to spatially localized areas of infection. This could explain the localized areas of ground glass infiltrates observed in chest computed tomography in minimally symptomatic patients with COVID-19 39 . We speculate that alveolar macrophages harboring SARS-CoV-2 might spread virus between alveoli. For example, tissue-resident alveolar macrophages, once thought to be sessile, were recently shown to travel between alveoli through pores of Kohn, particularly during viral infection 40 . In each new area of infection, positive feedback loops between alveolar macrophages harboring the virus and activated T cells could promote persistent injury and inflammation.

Our model of SARS-CoV-2 pneumonia as a slowly-progressive, spatially-restricted infection explains some of the unusual clinical features of COVID-19. Most notably, the clinical course of severe SARS-CoV-2 pneumonia is much longer than that of other respiratory viruses. The time from the onset of symptoms to respiratory failure in patients with SARS-CoV-2 infection is 6-12 days, compared with 1-3 days or even less in patients with influenza A virus infection 4, 41 . Furthermore, in our cohort the duration of mechanical ventilation and ICU stay were much longer in patients with severe SARS-CoV-2 pneumonia, compared with other respiratory pathogens causing pneumonia, despite a similar severity of illness and mortality. This longer clinical course might also explain some of the systemic complications of the disease. Although sparsely sampled, the levels of inflammatory biomarkers in the blood were similar in patients with COVID-19 and those with other etiologies of pneumonia in our cohort, confirming more recent systematic reports 42, 43 . This observation raises the intriguing possibility that the increased number of systemic complications observed in patients with SARS-CoV-2 pneumonia are related to prolonged, rather than higher level, exposure to circulating inflammatory cytokines.

In summary, we present a dataset that supports a testable model, in which alveolar macrophages harboring SARS-CoV-2 form positive feedback loops with IFNγ-secreting T cells to promote alveolitis in patients with severe COVID-19.

All human subjects research was approved by the Northwestern University Institutional Review Board. Samples from patients with COVID-19, viral pneumonia, other pneumonia, and non-pneumonia controls were collected from participants enrolled in the Successful Clinical Response In Pneumonia Therapy (SCRIPT) study STU00204868. Alveolar macrophages from healthy volunteers were obtained under study STU00206783. Autopsy tissues were obtained per usual protocols and analyzed under study STU00079445. All study participants or their surrogates provided informed consent. Patients ≥ 18 years of age with suspicion of pneumonia based on clinical criteria (including but not limited to fever, radiographic infiltrate, and respiratory secretions) were screened for enrollment into the SCRIPT study. Inability to safely perform BAL or NBBAL were considered exclusion criteria 44 . In our center, patients with respiratory failure are intubated based on the judgement of bedside clinicians for worsening hypoxemia, hypercapnia, or work of breathing refractory to high-flow oxygen or non-invasive ventilation modes. Extubation occurs based on the judgement of bedside clinicians following a protocol-driven trial of spontaneous breathing in patients demonstrating physiologic improvement in their cardiorespiratory status during their period of mechanical ventilation.

We collected data and samples from patients enrolled in SCRIPT from June 15, 2018 to July 6, 2020 in our intensive care unit (ICU) at Northwestern Memorial Hospital in Chicago. We prospectively enrolled 88 of the 179 patients with SARS-CoV-2-induced pneumonia and respiratory failure requiring mechanical ventilation in our intensive care unit (Fig. 1b , Extended Data Fig. 1a , b; Extended Data Table 1 ), all but one of whom had been discharged at the time of our submission. Management of patients with COVID-19 was guided by protocols published and updated on the Northwestern Medicine intranet as new information became available over the pandemic. Clinical laboratory testing including studies ordered on BAL fluid was at the discretion of the care team; however, quantitative cultures, multiplex PCR (BioFire Film Array Respiratory 2 panel), and automated cell count and differential were recommended by local ICU protocols. Most patients also underwent urinary antigen testing for Streptococcus pneumoniae and Legionella pneumophilia serogroup 1 on admission. Clinicians were encouraged to manage all patients, including those with COVID-19, according to ARDSNetwork protocols including the use of a higher PEEP/lower FiO 2 strategy for those with severe hypoxemia 45, 46 . Prone positioning (16 hours per day) was performed in all patients with a PaO 2 /FiO 2 <150 who did not have contraindications 47 . In those who had a response to prone positioning evidenced by improved oxygenation, prone positioning was repeated. Esophageal balloon catheters (Cooper Surgical) were placed at the discretion of the care team to estimate transpulmonary pressure and optimize PEEP, particularly in patients with a higher-than-normal BMI.

Autopsy specimen used for sm-FISH (RNAscope) (Fig. 4i) : An 81-year old woman with end-stage renal disease and cirrhosis was admitted for a fever of 38.5°C. She had a positive nasopharyngeal swab for SARS-CoV-2. The patient developed increased O 2 requirements and was subsequently transferred to the COVID ICU. In the ICU, the decedent developed hypotension to 60s/40s and after discussion with the clinical team, the decedent's family elected to focus on comfort care. The patient died 8 days after admission.

Consent was obtained from patients or their surrogates for bronchoscopic procedures. Bronchoscopic BAL was performed in intubated ICU patients with flexible, single-use Ambu aScope (Ambu) devices. Patients were given sedation and topical anesthetic at the physician proceduralist's discretion. Vital signs were monitored continuously throughout the procedure. The bronchoscope was wedged in the segment of interest based on available chest imaging or intra-procedure observations, aliquots of 30 ml of normal saline at a time, generally 90-120 ml total, were instilled and aspirated back. The fluid returned following the first aliquot was routinely discarded. Samples were split (if sufficient return volume was available) and sent for clinical studies and an aliquot reserved for research. A similar procedure was applied to non-bronchoscopic BAL (NBBAL); however, NBBAL was performed with directional (lateral) but not visual guidance, and as usual procedural care by a respiratory therapist rather than a pulmonologist 44 .

For bronchoscopies performed in COVID-19 patients, additional precautions were taken to minimize the risk to healthcare workers including only having essential providers present in the room, clamping of the endotracheal tube, transient disconnection of the inspiratory limb from the ventilator, and preloading of the bronchoscope through the adapter 48 . Sedation and neuromuscular blockade to prevent cough, was administered for these procedures at the physician's discretion. In most cases of early bronchoscopy, the procedure was performed immediately after intubation, taking advantage of neuromuscular blockade administered for the intubation procedure.

For all patients with COVID-19, samples were collected from regions of greatest chest radiograph abnormality by a critical care physician using a disposable bronchoscope. The majority of samples prior to the pandemic were collected by respiratory therapists using a non-bronchoscopic bronchoalveolar lavage (NBBAL) catheter that is the same diameter as a standard bronchoscope with the catheter directed to the most radiographically affected lung. For both bronchoscopic and NBBAL, the recommended instillate volume was 120 ml and the initial aliquot was discarded if adequate return was obtained 44 .

Five critical care physicians (JMK, COP, BDS, JMW, RGW) retrospectively adjudicated patients as COVID-19 pneumonia, non-COVID-19 viral pneumonia, pneumonia secondary to other pathogens, or non-pneumonia controls (intubated for reasons other than pneumonia), according to a standardized adjudication procedure (the adjudication protocol can be found in Supplemental Data File 8). Non-pneumonia controls were defined as patients who underwent BAL to exclude pneumonia but had negative quantitative cultures, a negative multiplex PCR for viral and bacterial pathogens (when available) and negative urine antigens for Streptococcus pneumoniae and Legionella pneumophilia serogroup 1, as well as an alternative diagnosis. The treating clinician's impression was considered, but concordance was not required. Subsequent course and the entirety of the clinical record was used for adjudication. Some of the patients adjudicated as non-pneumonia controls developed ventilator-associated pneumonia later in their clinical course. Viral pneumonia was diagnosed based on detection of a respiratory viral pathogen from either a nasopharyngeal swab or BAL fluid in the appropriate clinical setting. Bacterial pneumonia was defined as positive quantitative cultures with > 10^2 colony forming units/ml, detection of a bacterial pathogen by PCR analysis of BAL fluid or a positive urine antigen. Over the course of the study, BAL fluid was analyzed using an MRSA PCR (MRSA/SA SSTI) and the BioFire FilmArray Respiratory 2 (RP2) Panel and Pneumonia panels. SARS-CoV-2 was detected with a variety of assay platforms including the Cepheid Gene Expert, Abbott ID NOW, Becton-Dickinson, and a locally-developed and validated PCR. For some patients without COVID-19, the diagnosis of pneumonia was made based on clinical suspicion, radiographic findings, and response to antimicrobial therapy in the absence of an identified pathogen. Ventilator-associated pneumonia was diagnosed as detection of a new respiratory pathogen using quantitative culture or PCR more than 48 hours after intubation, the detection of a new respiratory pathogen on serial BAL samples, or the reappearance of a respiratory pathogen after a negative BAL on a subsequent study. Clinical laboratory data were obtained from the Northwestern Medicine Enterprise Data Warehouse using Structured Query Language (SQL). APS and SOFA scores were generated from the Electronic Health Record using previously validated programming.

NBBAL and BAL samples were filtered through a 70-μm cell strainer, pelleted by centrifugation at 300 rcf for 10 min at 4°C, followed by hypotonic lysis of red blood cells with 2 ml of BD PharmLyse reagent for 2 minutes. Lysis was stopped by adding 13 ml of MACS buffer (Miltenyi Biotech). Cells were pelleted again and resuspended in 100 μl of 1:10 Fc-Block (Human TruStain FcX, Biolegend) in MACS buffer, and a 10-μl aliquot was taken for counting using K2 Cellometer (Nexcelom) with AO/PI reagent. The volume of Fc-Block was adjusted so the concentration of cells was always less than 5×10 7 cells/ml and the fluorophore-conjugated antibody cocktail was added in 1:1 ratio (Extended Data Table 3 ). After incubation at 4°C for 30 minutes, cells were washed with 5 ml of MACS buffer, pelleted by centrifugation, and resuspended in 500 μl of MACS buffer with 2 μl of SYTOX Green viability dye (ThermoFisher). Cells were sorted on a FACS Aria III SORP instrument using a 100-μm nozzle at 20 psi. Cells were sorted into 300 μl of MACS buffer for bulk RNA-seq or 300 μl of 2% BSA in PBS for single-cell RNA-seq. Sample processing was performed in BSL-2 facility using BSL-3 practices. Analysis of the flow cytometry data was performed using FlowJo 10.6.2. using uniform sequential gating strategy (Extended Data Fig. 2 ) reviewed by three investigators (SS, BDS, AVM). Immune populations were defined using canonical markers as shown in Extended Data Fig. 2 44, 49 . Alveolar macrophages were defined by the expression of CD206 (mannose receptor). We further subdivided alveolar macrophages into CD206 lo alveolar macrophages, which represent differentiating monocytederived alveolar macrophages, and CD206 hi alveolar macrophages, which include both tissue-resident alveolar macrophages, present in the lung prior to the onset of pneumonia, and mature monocyte-derived alveolar macrophages. Since CD206 hi alveolar macrophages can be found in BAL fluid from both healthy volunteers and patients across different types of pneumonia, and the presence of CD206 lo alveolar macrophages varies across the patients with pneumonia 49-51 , we focused our transcriptomic analysis on CD206 hi alveolar macrophages. Abundance of specific populations in individual BAL fluid samples can be found in Supplemental Data File 9.

Bulk RNA-seq of flow cytometry-sorted alveolar macrophages:

Immediately after sorting, cells were pelleted by centrifugation and lysed in 350 μl of RLT Plus lysis buffer (Qiagen) supplemented with 2-mercaptoethanol. Lysates were stored at −80°C until RNA isolation using the AllPrep DNA/RNA Micro kit according to the manufacturer's protocol (Qiagen). RNA quality and quantity were assessed using TapeStation 4200 High Sensitivity RNA tapes (Agilent), and RNA-seq libraries were prepared from 250 pg of total RNA using SMARTer Stranded Total RNA-seq Kit v2 (Takara Bio). Libraries were pooled using dual indexing and sequenced on a NextSeq 500 instrument (Illumina), 75 cycles, single-end, to an average sequencing depth of 19.55M reads.

FASTQ files were generated using bcl2fastq (Illumina). To enable detection of viral RNA, a custom hybrid genome was prepared by joining FASTA, GFF, and GTF files for GRCh37.87, SARS-CoV-2 (NC_045512.2), and Influenza A/California/07/2009 (GCF_001343785.1), which was the dominant strain of influenza throughout BAL fluid collection at our hospital 52 . An additional negative strand transcript spanning the entirety of the SARS-CoV-2 genome was then added to the GTF and GFF files to enable detection of SARS-CoV-2 replication. Normalized counts tables later revealed high enrichment of SARS-CoV-2 transcripts in diagnosed COVID-19 patients, and enrichment of IAV genes in patients marked as other viral pneumonia. Of note, since our alveolar macrophage sorting strategy for bulk RNA-seq (Extended Data Fig. 2a,b) only focused on CD206 hi cells, our bulk RNA-seq data likely underestimate infection of alveolar macrophages infected with SARS-CoV-2 (Fig. 2d) .

To facilitate reproducible analysis, samples were processed using the publicly available nfcore/RNA-seq pipeline version 1.4.2 implemented in Nextflow 19.10.0 using Singularity 3.2.1-1 with the minimal command nextflow run nf-core/rnaseq -r 1.4.2 -singleEnd -profile singularity -reverseStranded --three_prime_clip_r2 3 53-55 . Briefly, lane-level reads were trimmed using trimGalore! 0.6.4 and aligned to the hybrid genome described above using STAR 2.6.1d 56 . Gene-level assignment was then performed using featureCounts 1.6.4 57 . Putative sample swaps were identified first by comparing known patient sex with sex determined by levels of XIST and RPS4Y1 expression, followed by single nucleotide polymorphism analysis with NGSCheckMate version 1.0.0 in FASTQ mode using default settings 58 . Samples exhibiting unexpected correlation were excluded from analysis.

All analysis was performed using custom scripts in R version 3.6.3 using the DESeq2 version 1.26.0 framework 59 . Correspondence between lanes was first confirmed by principal component analysis before merging counts using the command collapseReplicates(). One outlier sample from the Other Pneumonia group with low RIN score and exhibiting extreme deviation on PCA and poor alignment and assignment metrics was excluded from downstream analysis. For differential expression analysis (DEA), both proportion of alveolar macrophage from flow cytometry data and diagnosis were used as explanatory factors. A "local" model of gene dispersion was employed as this better fit dispersion trends without obvious overfitting, and gene outlier replacement was disabled; otherwise default settings were used. See code for details.

A custom-built function was used (available at https://github.com/NUPulmonary/utils/blob/ master/R/k_means_Figure.R) for k-means clustering. Briefly, variable genes were identified using a likelihood-ratio test (LRT) with local estimates of gene dispersion in DESeq2 with diagnosis as the full model as well as a reduced model corresponding to intercept alone.

Genes with q ≥ 0.05 were discarded. Extant genes were then clustered using the Hartigan-Wong method with 25 random sets and a maximum of 1000 iterations using the kmeans function in R stats 3.6.3. Samples were then clustered using Ward's method and plotted using pheatmap version 1.0.12. GO term enrichment was then determined using Fisher's exact test in topGO version 2.38.1, with org.Hs.eg.db version 3.10.0 and GO.db version 3.10.0 as references.

WGCNA was performed manually using WGCNA version 1.69 with default settings unless otherwise noted 60 . Genes with counts > 5 and detection in at least 10% of samples were included in the analysis. To best capture patterns of co-regulation, a signed network was used. Using the pickSoftThreshold function, we empirically determined a soft threshold of 7 to best fit the network structure. A minimum module size of 30 was chosen to isolate relatively large gene modules. Module eigengenes were then related back to patient and sample metadata using biweight midcorrelation. Module GO enrichment was then determined as above using Fisher's exact test in topGO version 2.38.1, with org.Hs.eg.db version 3.10.0 as a reference. UMAP plotting was performed using uwot version 0.1.8 using the first 20 principal components of the same genes used in WGCNA analysis after Zscaling and centering, with a minimum distance of 0.2 61 . Default parameters were otherwise used.

For patients with COVID-19 we limited our analysis to samples in which flow cytometry identified distinct populations of CD206 hi and CD206 lo macrophages (Patient 1, 2, 3, 4, 5, 7, 8, 9, A and B). We included two additional patients, one with bacterial pneumonia secondary to infection with Pseudomonas aeruginosa and Acinetobacter baumannii (assigned as "other pneumonia", Patient 6) and one intubated for airway protection to facilitate endoscopy for severe gastrointestinal bleeding without pneumonia (assigned as a "non-pneumonia control", Patient C) to examine nonspecific effects of inflammation and mechanical ventilation, respectively, on transcriptomic signatures. Samples were enriched via flow cytometry sorting for live cells, excluding granulocytes. Cells were sorted into 2% BSA in DPBS, pelleted by centrifugation at 400 rcf for 5 min at 4°C, resuspended in 0.1% BSA in DPBS to ~1000 cells/μl concentration. Concentration was confirmed using K2 Cellometer (Nexcelom) with AO/PI reagent and cells were loaded on 10x Genomics Chip A with Chromium Single Cell 5' gel beads and reagents (10x Genomics) aiming to capture ~5,000-10,000 cells per library. Libraries were prepared according to the manufacturer's protocol (10x Genomics, CG000086_RevM). After quality checks, single-cell RNA-seq libraries were pooled and sequenced on a NovaSeq 6000 instrument.

Data was processed using the Cell Ranger 3.1.0 pipeline (10x Genomics). To enable detection of viral RNA, reads were aligned to a custom hybrid genome containing GRCh38.93 and SARS-CoV-2 (NC_045512.2). An additional negative-strand transcript spanning the entirety of the SARS-CoV-2 genome was then added to the GTF and GFF files to enable detection of SARS-CoV-2 replication. Data were processed using Scanpy v1.5.1 62 , doublets were detected with scrublet v0.2.1 63 and removed, ambient RNA was corrected with FastCAR (https://github.com/LungCellAtlas/FastCAR), and multisample integration was performed with BBKNN v1.3.12 64 . Only human transcripts were used during integration, selection of highly variable genes and clustering, SARS-CoV-2 transcripts did not influence clustering. Gene set enrichment analysis was performed with signatures retrieved from the gsea-msigdb.org website 65 using following terms: HALLMARK_INTERFERON_GAMMA_RESPONSE M5913, HALLMARK_INTERFERON_ALPHA_RESPONSE M5911. Computations were automated with snakemake v5.5.4 66 .

With exclusion of patients A and B, single-cell RNA-seq was performed without multiplexing, using cells from a single patient per single 10x Genomics chip channel. Cells from patients A and B were split into three 10x Genomics chip channels: sample 14 contained cells from patient A, sample 15 contained cells from patient B and sample 16 contained cells from patients A and B multiplexed together. To assign cells from this sample to patients, we used souporcell v2.0 67 (commit 34eade2ad3a361f045a31f53fee58c2e0c49423f) with the list of common variants for GRCh38 genome, provided on the souporcell page. We ran souporcell for samples 14, 15 and 16 with the number of clusters k=2. We computed Pearson correlation between integercoded single-nucleotide polymorphisms in genotypic clusters in sample pairs 14-16 and 15-16 to determine which genotypic clusters come from the same patients. Genotypic doublets and unassigned cells were discarded. See code for details.

Deconvolution of bulk RNA-seq alveolar macrophage signatures was performed using AutoGeneS v1.0.3 68 and signatures derived from the integrated single-cell RNA-seq object. We used an integrated single-cell RNA-seq object containing the first six subjects included into analysis (patients 1-6) to train the AutoGeneS model. Signatures were automatically identified from 4500 highly variable genes with function optimize(ngen=200, seed=0, nfeatures=2000, mode="fixed") (see code at https://github.com/NUPulmonary/2020_Grant). The model was then applied to bulk RNA-seq data to estimate the proportion of specific cell types using regression. We used bulk RNA-seq samples from healthy volunteers (which contain only tissue-resident alveolar macrophages and do not contain inflammatory monocyte-derived alveolar macrophages) to validate and optimize selection of the clusterspecific genes and deconvolution results.

RNAscope Multiplex V2 manual assay from ACDbio was performed on paraffin-embedded 5 μm slices of lung tissue using mild digest times according to manufacturer instructions as we have described. Probes used were RNAscope Probe-V-nCoV2019-S-C3 (catalog number 848561) with Akoya Bio Opal Dye 520 using the 488 nm laser line and RNAscope Probe-nCoV2019-orf1ab-sense-C2 (catalog number 859151) with Opal Dye 690 using 640 nm laser line. After RNAscope assay was complete, slides were washed in TBST (1X TBS pH 7.6 with 0.1% Tween-20) for 2 minutes with agitation twice. Slides were incubated in the dark at room temperature for 30 minutes with 10% normal goat serum in 1X TBS with 1% bovine serum albumin (BSA). The blocking solution was removed from slides via gentle flicking. Slides were then incubated in primary antibody solution containing anti-CD206 antibody (clone C-10) conjugated to AF546 (Santa Cruz Biotechnology Cat# sc-376232, RRID:AB_10989352) at 1:100 dilutions in TBS 1% BSA for 1 h at room temperature in the dark. Slides were rinsed using TBST for 5 minutes with agitation twice. Slides were rinsed in TBST buffer for 5 minutes twice. Slides were then mounted and dried overnight. Images were acquired at the Center for Advanced Microscopy at Northwestern University Feinberg School of Medicine using the Nikon W1-Spinning Disk Confocal microscope. Nucleus was added to the images using machine-based learning network trained on one patient using DAPI and brightfield images in Nikon Elements. Final images were rendered using Fiji.

Statistical analysis was performed using base R version 3.6.3 with tidyverse version 1.3.0 69 and Python 3.6. For all comparisons, normality was first assessed using a Shapiro-Wilk test and manual examination of distributions. For parameters exhibiting a clear lack of normality, nonparametric tests were employed. In cases of multiple testing, P-values were corrected using false-discovery rate (FDR) correction. In Python, we used the mannwhitneyu function from scipy package version 1.3.1 70 for nonparametric tests, and corrected for multiple testing with the statsmodels package version 0.10.1 71 . Adjusted P-values < 0.05 were considered significant. Two-sided statistical tests were performed in all cases.

Plotting was performed in figures 1, 2, 3, extended data figures 1, 2, and 3 using ggplot2 version 3.3.1 unless otherwise noted. Comparisons for these figures were added using ggsignif version 0.6.0. Heatmaps on figures 2 and 3 were generated using pheatmap version 1.0.12. Sankey/Alluvial plots on Extended Data Fig. 1 were generated using ggalluvial version 0.12.0 72 . Figure layouts for Figures 1, 2, 3, 4 , and Extended Data Figures 1, and 3 were generated using patchwork version 1.01 and edited in Adobe Illustrator 2021. Figure 4 and extended data figures 4 and 5 were generated with matplotlib v3.2.1 73 . For all boxplots shown, box limitsq represent the interquartile range (IQR) with a centerline at the median. Whiskers represent the largest point ≤ 1.5 * IQR. All points are overlaid.

First, this is an observational study, and in the absence of a specific intervention targeting a necessary component of our model, our data are hypothesis-generating. Moreover, our observational cohorts are heterogeneous with respect to treatments received and other processes of care. Second, while we made every attempt to standardize BAL fluid volumes, the number of alveoli sampled and the return volume during both bronchoscopic and nonbronchoscopic BAL is variable. Hence, our observations are relative rather than quantitative. Third, our flow cytometry panels, while rigorous, were limited by the number of antibodies that could be used for high volume characterization of clinical samples. Fourth, our BAL samples were collected as part of clinical care; therefore, sicker patients were more likely to be sampled. Finally, while we made every effort to standardize care for patients with SARS-CoV-2 pneumonia in our ICU, some of our patients were enrolled in clinical trials of remdesivir or sarilumab, many patients received unproven therapies off label including hydroxychloroquine and tocilizumab, and our study largely preceded reports on the use of steroids in patients with severe SARS-CoV-2 pneumonia (Extended Data Table 1 ). Despite these limitations, our systems approach to understand SARS-CoV-2 pathobiology provides a model with testable predictions that can serve as a template for the design of targeted interventions in patients with severe disease.

Extended Data Fig. 1 : Overview of the study and biomarkers.

We compared BAL fluid obtained sequentially from 88 patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation with 38 patients with confirmed pneumonia Grant secondary to other respiratory viruses (other viral pneumonia), 173 patients with non-viral pneumonia (other pneumonia) and 42 mechanically ventilated patients without pneumonia undergoing BAL (non-pneumonia controls). a. Sankey diagram illustrating steps in analysis performed for at least one BAL sample for participants with COVID-19, other viral pneumonia, non-viral pneumonia (other pneumonia), non-pneumonia controls, and healthy controls. This includes samples from patients 1) enrolled in the SCRIPT study (346 patients), 2) analyzed via flow cytometry (241 patients), 3) for whom bulk RNA-seq was performed on flow cytometry-sorted alveolar macrophages (181 patients) and 4) for whom single-cell RNA-seq was performed on cells from BAL fluid (10 patients with SARS-CoV-2 pneumonia, 1 patient with bacterial pneumonia and 1 patient intubated for reasons other than pneumonia (gastrointestinal bleeding requiring endoscopy, a non-pneumonia control)). Some samples were cryopreserved and sorted post-cryorecovery. Because cryopreservation affects the number of neutrophils, these samples were not included in flow cytometric analysis but were used for bulk RNA-seq profiling of flow cytometry-sorted alveolar macrophages. a. We developed a gating strategy that allowed us to quantify immune cell populations including monocytes, alveolar macrophage subsets, and T cell subsets. Importantly, we defined alveolar macrophages by their expression of CD206, subdividing them into early monocyte-derived alveolar macrophages (CD206 lo ) and more mature (CD206 hi ) alveolar macrophages. T cells were identified as CD3-positive and further subdivided into CD4+ and CD8+ T cells. Tregs were identified as CD3+CD4+CD25+CD127−. Neutrophils were identified as CD15+ cells. Monocytes were identified as HLA-DR+CD4+CD206− cells. Of note, only CD206 hi alveolar macrophages were flow cytometry-sorted for bulk RNA-seq analysis (Figs. 2 and 3) ; hence, early monocyte-derived alveolar macrophages (MoAM1 and MoAM2 in our single-cell RNA-seq data, Fig. 4a-h) were not captured in bulk RNA-seq.

Representative sample from a patient without neutrophilia is shown. Solid red arrows indicate direct sequential gating, dashed blue arrows indicate Boolean "not" gates. Numbers on plots indicate the percentage of the parent population. Axis labels indicate laser line (UV -355 nm, V -405 nm, B -488 nm, YG -552 nm, R -640 nm), bandpass filter, fluorochrome and antigen/dye. b. Representative sample from a patient with neutrophilia illustrates loss of CD206 hi alveolar macrophages and influx of monocyte-derived CD206 lo alveolar macrophages. c-d. Contour plot and histogram overlays illustrating forward (FSC) and side scatter (SSC) properties of the CD3+ T cells (CD3), CD15+ neutrophils (CD15), monocytes, CD206 lo alveolar macrophages (CD206 lo ), and CD206 hi alveolar macrophages (CD206 hi ) in the representative sample from a patient without neutrophilia (c.) and with neutrophilia (d.). Note that neutrophils have higher side scatter than monocytes. e. Representative contour plots illustrating a sample with two distinct populations of CD206 hi alveolar macrophages. Single-cell RNA-seq analysis (Fig. 4a-h) Column headers are color-coded by the diagnosis, duration of mechanical ventilation (white color indicates chronically ventilated patients), and presence or absence of superinfection ("Infection Status"). "Infection Status" refers only to the "COVID-19" and "Other Viral Pneumonia" groups; blanks in these groups refer to samples for which microbiology data were incomplete and infectious status could not be determined. "Viral infection only" refers to viral pathogens as the only detected pathogen in a sample and "Viral infection with bacterial/fungal superinfection" refers to detection of a viral pathogen with one or more bacterial or fungal co-pathogens. b. Comparison of percentage of CD206 lo and CD206 hi alveolar macrophages between early (<48 hours after intubation) and late (>48 hours of mechanical ventilation) samples (q < 0.05, pairwise Wilcoxon rank-sum tests with FDR correction). c. Comparison of CD4+ and CD8+ T cell and neutrophil abundance in the COVID-19 group, with and without superinfection in early and late sampling. Superinfection is represented by lighter bars. Differences between groups are not significant after FDR correction. Fig. 5 . SARS-CoV-2 pneumonia is characterized by a persistent interferonresponse signature in alveolar macrophages.

a. k-means clustering of the 2,323 significantly variable genes (q < 0.05, likelihood-ratio test) across diagnosis, columns represent each individual patient, grouped by diagnosis and ordered by day from first intubation. "Infection Status" refers only to the "COVID-19" and "Other Viral Pneumonia" groups; blanks in these groups refer to samples for which microbiology data were incomplete and infectious status could not be determined. "Viral infection only" refers to viral pathogens as the only detected pathogen in a sample and "Viral infection with bacterial/fungal superinfection" refers to detection of a viral pathogen with one or more bacterial or fungal co-pathogens. Representative genes and GO biological processes are shown for each cluster. Column headers are color-coded by diagnosis and duration of mechanical ventilation (white color indicates chronically ventilated patients). b. Grant Expression of selected genes between the groups. Note that expression of IL6 is not increased in any group. All significant comparisons are shown (q < 0.05, Wald test with FDR correction in DESeq2). c. Weighted gene co-expression network analysis (WGCNA). Flow cytometry panels, reagents and instruments configuration. a. Hierarchical clustering of flow cytometry data from BAL samples collected within 48 hours of intubation. Column headers are color-coded by the diagnosis and presence or absence of co-infection ("Infection Status"). "Infection Status" refers only to the "COVID-19" and "Other Viral Pneumonia" groups. "Viral infection only" refers to viral pathogens as the only detected pathogen in a sample and "Viral infection with bacterial/ fungal co-infection" refers to detection of a viral pathogen with one or more bacterial or fungal co-pathogens. Samples were clustered by Euclidean distance using Ward's method. b.

Proportions of cells detected within 48 hours of intubation (q < 0.05, pairwise Wilcoxon rank-sum tests with FDR correction). Comparisons are not significant unless otherwise noted. c. k-means clustering of the 1,194 significantly variable genes (q < 0.05, likelihoodratio test) across diagnosis. Columns represent each individual sample and are clustered using Ward's method. Column headers are color-coded by the diagnosis and presence or absence of a co-infecting pathogen ("Infection Status"). "Infection Status" refers only to the "COVID-19" and "Other Viral Pneumonia" groups; blanks in these groups refer to samples for which microbiology data were incomplete and infectious status could not be determined. "Viral infection only" refers to viral pathogens as the only detected pathogen in a sample and "Viral infection with bacterial/fungal co-infection" refers to detection of a viral pathogen with one or more bacterial or fungal co-pathogens. Representative genes and GO biological processes are shown for each cluster. a. Hierarchical clustering of flow cytometry analysis of BAL samples from all time points from patients with serial sampling (n > 1) based on their composition. Column headers are color-coded by the diagnosis, patient, duration of mechanical ventilation, and presence or absence of superinfection ("Infection Status"). "Infection Status" refers only to the "COVID-19" and "Other Viral Pneumonia" groups; blanks in these groups refer to samples for which microbiology data were incomplete and infectious status could not be determined. "Viral infection only" refers to viral pathogens as the only detected pathogen in a sample and "Viral infection with bacterial/fungal superinfection" refers to detection of a viral pathogen with one or more bacterial or fungal co-pathogens. Samples were clustered by Euclidean distance using Ward's method. b. Comparison of percentage of CD4+ and CD8+ T cells and neutrophils between early (<48 hours after intubation) and late (>48 hours of mechanical ventilation) samples (q < 0.05, pairwise Wilcoxon rank-sum tests with FDR correction). c. k-means clustering of the 2,323 significantly variable genes (q < 0.05, likelihood-ratio test) across diagnosis, columns represent each individual patient and clustered using Ward's method. Representative genes and GO biological processes are shown for each cluster. Column headers are color-coded by the diagnosis, duration of mechanical ventilation (white color indicates chronically ventilated patients), and presence or absence of superinfection ("Infection Status"). "Infection Status", "Viral infection only" and "Viral infection with bacterial/fungal superinfection" are as in panel a. 

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

COVID-19 Does Not Lead to a "Typical

Real estimates of mortality following COVID-19 infection

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

National Heart, Lung, and Blood Institute PETAL Clinical Trials Network et al. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome

Budinger GRS & Others. The role of macrophages in the resolution of inflammation

The Architecture of SARS-CoV-2 Transcriptome

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis

Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis

Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus

Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis

Metformin Targets Mitochondrial Electron Transport to Reduce Air-Pollution-Induced Thrombosis

Wort SJ Thrombosis and COVID-19 pneumonia: the clot thickens! The European respiratory journal: official journal of the European Society for

Immunology of COVID-19: Current State of the Science

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment

Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis

Effects of Influenza on Alveolar Macrophage Viability Are Dependent on Mouse Genetic Strain

SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcγR pathway

Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States

Perlman S Lessons for COVID-19 Immunity from Other Coronavirus Infections

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Hammad H Division of labor between lung dendritic cells and macrophages in the defense against pulmonary infections

T-Cell response profiling to biological threat agents including the SARS coronavirus

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Low avidity CD4+ T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19

EJ Prevalence of Asymptomatic SARS-CoV-2 Infection: A Narrative Review

Patrolling Alveolar Macrophages Conceal Bacteria from the Immune System to Maintain Homeostasis

Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

Critically Ill Patients With COVID-19 and Other Conditions

pairwise Wilcoxon rank-sum tests with FDR correction). i. ICU length of stay (pairwise t-tests with FDR correction). j. The duration of mechanical ventilation (pairwise ttests with FDR correction). k. Mortality in patients with COVID-19 was similar to patients in other groups

Author manuscript; available in PMC

Density projection plots, expression averaged within hexagonal areas on UMAP. h. Heatmap demonstrating selected differentially expressed genes between two subsets of tissue

Combined immunofluorescence microscopy for CD206, a marker of mature macrophages (red arrows), and smFISH (RNAscope) for positive-(yellow arrowheads) and negative-strand (cyan doublehead arrows) SARS-CoV-2 transcripts. Inserts show infected and non-infected CD206-positive alveolar macrophages in the adjacent alveoli

Author manuscript; available in PMC

 Table 1: Demographics of the SCRIPT cohort, grouped by diagnosis. All patients were admitted to Northwestern Memorial Hospital in Chicago between June 15, 2018 and July 6, 2020. Bronchoscopy was most commonly performed as part of routine clinical care to guide antimicrobial therapy. Patients with ARDS were managed using a high PEEP, low tidal volume ventilation strategy and were ventilated prone when suggested by ARDSnet guidelines. Patients received steroids and off label IL-6 receptor antagonists (tocilizumab or sarilumab) at the discretion of the clinical team. Any hydroxychloroquine use is reported, but hydroxychloroquine was routinely stopped upon ICU admission. Some patients were enrolled in multicenter placebo-controlled trials of remdesivir or sarilumab, treatment assignment is blinded.

Non 

Refer to Web version on PubMed Central for supplementary material.